Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

188.38 -0.21 (-0.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Biogen Idec

< Previous 1 2
...
33 34 35 36 37 38 39 40 Next >
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
Exposures Product Safety
Biogen: Q2 Earnings Insights
Shares of Biogen (NASDAQ:BIIB) fell 0.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 44.64% over the past year to... 
Via Benzinga
Biogen's Q2 Profit Falls 70% As Tecfidera Competition Hits Topline
Biogen Inc (NASDAQ: BIIB) posted Q2 adjusted EPS of $5.68 ahead of the consensus estimate of $4.55, but quarterly profit fell around 71% Y/Y to $448.5 million as... 
Via Benzinga
What 18 Analyst Ratings Have To Say About Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observe... 
Via Benzinga
Biogen Earnings, Sales Top Q2 Views; Stock Rises
Biogen earnings and sales fell, but beat Q2 views. Biogen stock rose slightly. 
Via Investor's Business Daily
Here's Why Cassava Sciences Is Surging Today
Investors are excited about upcoming presentations scheduled for the annual Alzheimer's Association International Conference. 
Via The Motley Fool
Exposures Product Safety
SAVA Stock: Two Dates Cassava Investors Need to Mark on Their Calendars
SAVA stock is flying upward today as investors clamor to hear information around two new products. Investors should save two upcoming dates. 
Via InvestorPlace
Understanding Biogen's Unusual Options Activity
Biogen (NASDAQ:BIIB) shares experienced unusual options activity on Wednesday. The stock price moved down to $322.07 following the option alert. Sentiment: BULLISH Option Type:... 
Via Benzinga
Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications
Mirimus Inc has collaborated with Biogen Inc (NASDAQ: BIIB) to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications.... 
Via Benzinga
Earnings Scheduled For July 22, 2021
Companies Reporting Before The Bell • Champions Oncology, Inc. - Common Stock (NASDAQ:CSBR) is estimated to report earnings for its fourth quarter. • MarineMax,... 
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Both of these companies have successfully developed breakthrough medicines. 
Via The Motley Fool
Carnival And American Airlines Lead The SPY Higher Tuesday
U.S. indices were trading higher Tuesday amid a rebound in reopening stocks, which dipped Monday amid Delta variant concerns. The... 
Via Benzinga
Is It Too Late to Buy Biogen Stock?
This biotech company could be a diamond in the rough -- for investors who can tolerate its share price volatility. 
Via The Motley Fool
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week stoked rate hike fears,... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
Exposures Product Safety
4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021
There are important things to watch with each of these stocks. 
Via The Motley Fool
Exposures COVID-19
Week In Review: Innocare Strikes $937 Million Deal With Biogen For BTK Inhibitor
Beijing InnoCare out-licensed ex-China rights for its BTK inhibitor to Biogen​​ in a $937.5 million deal. Biogen will pay $125 million upfront and up to $812.5 million in milestones, plus royalties. 
Via Talk Markets
Stock Market Rally Struggles Outside Apple; JPMorgan, Goldman, UnitedHealth, Taiwan Semi Are Key Earnings
Apple hit record highs, but the stock market quietly struggled this week. JPMorgan, Goldman, Taiwan Semi kicked off earnings. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
FibroGen Stock Collapses After FDA Panel Rejects Anemia Treatment
A FDA panel voted resoundingly against recommending approval for an anemia treatment from FibroGen, and FGEN stock tanked on Friday. 
Via Investor's Business Daily
Exposures Product Safety
Better Biotech Stock: Biogen vs. Annovis Bio
Both are making Alzheimer's drugs, but only one can claim success as of today. 
Via The Motley Fool
AMD And Biogen Lead The QQQ Lower Thursday
U.S. indices were trading lower Thursday as investors weigh Fed Chair Powell’s comments on inflation to the Senate banking panel. ... 
Via Benzinga
Topics Economy
Exposures Interest Rates
BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today
BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses. 
Via InvestorPlace
Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration
A pair of large hospitals have declined to administer Biogen Inc’s (NASDAQ: BIIB) Alzheimer’s treatment Aduhelm, Wall Street Journal reported. The... 
Via Benzinga
Biogen Stock Dives After Cleveland Clinic, Mount Sinai Ban Alzheimer's Drug Aduhelm
Biogen stock tumbled Thursday after the Cleveland Clinic and Mount Sinai said they won't administer the company's Alzheimer's drug, Aduhelm. 
Via Investor's Business Daily
Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News
Acting FDA Commissioner Janet Woodcock pushed back against media questions about the agency's controversial approval of Alzheimer's treatment, Aduhelm developed by ... 
Via Benzinga
Exposures Product Safety
Biogen Stock And The Aduhelm Drama: Will It Really Treat Alzheimer's?
The fate of Biogen stock is now intricately tied to the success — or failure — of its controversial Alzheimer's treatment, Aduhelm. 
Via Investor's Business Daily
US Medicare Starts Coverage Policy Review For Biogen's Aduhelm
The U.S. government started a review process for national Medicare coverage of Biogen Inc's (NASDAQ: BIIB) Alzheimer's drug, Aduhelm. The Centers for... 
Via Benzinga
Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate
Biogen Inc (NASDAQ: BIIB) is paying $125 million upfront to work on InnoCare Pharma Limited's orelabrutinib, a small oral molecule Bruton's... 
Via Benzinga
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
Tesla And Lam Research Lead The QQQ Higher Monday
Major U.S. indices managed to all finish with record closing highs Monday as investors continue to weigh last week’s sell-off over conce... 
Via Benzinga
< Previous 1 2
...
33 34 35 36 37 38 39 40 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.